Dr. Colin Dinney, principal investigator on the clinical trials that led to this approval of Adstiladrin, talks about this new adenovirus vectorbased gene therapy, how it works, how it's administered, and who would benefit from this latest treatment options for nonmuscle invasive bladder cancer (NMIBC).

Contents of this video:

00:00 Intro
04:49 Defining the BCG Unresponsive Population
07:06 What is Gene Therapy
14:32 Adenoviral Gene Therapy
21:40 Concerns Over the Safety of Gene Therapy
28:15 The Future of Adstiladrin